CDK4 and breast carcinoma: His earliest article on this area was a review published in 2014 in Current Opinion in Oncology, Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy (57), with an impact factor of 3.915 and 27 citations to date.